MDPI and ACS Style
Dodaran, M.S.; Banihashemi, S.R.; Es-haghi, A.; Mehrabadi, M.H.F.; Nofeli, M.; Mokarram, A.R.; Mokhberalsafa, L.; Sadeghi, F.; Ranjbar, A.; Ansarifar, A.;
et al. Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial. Vaccines 2023, 11, 455.
https://doi.org/10.3390/vaccines11020455
AMA Style
Dodaran MS, Banihashemi SR, Es-haghi A, Mehrabadi MHF, Nofeli M, Mokarram AR, Mokhberalsafa L, Sadeghi F, Ranjbar A, Ansarifar A,
et al. Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial. Vaccines. 2023; 11(2):455.
https://doi.org/10.3390/vaccines11020455
Chicago/Turabian Style
Dodaran, Masoud Solaymani, Seyed Reza Banihashemi, Ali Es-haghi, Mohammad Hossein Fallah Mehrabadi, Mojtaba Nofeli, Ali Rezaei Mokarram, Ladan Mokhberalsafa, Fariba Sadeghi, Alireza Ranjbar, Akram Ansarifar,
and et al. 2023. "Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial" Vaccines 11, no. 2: 455.
https://doi.org/10.3390/vaccines11020455